These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11786751)

  • 61. FDG uptake in liposclerosing myxofibrous tumor causes upstaging of Hodgkin lymphoma.
    Kim J; Chen W; Resnik C; Dilsizian V; Chen Q; Kimball AS
    Clin Nucl Med; 2015 Apr; 40(4):325-7. PubMed ID: 25290293
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
    Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
    Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lymphoma and tuberculosis: temporal evolution of dual pathology on sequential 18F-FDG PET/CT.
    Mukherjee A; Sharma P; Karunanithi S; Dhull VS; Kumar R
    Clin Nucl Med; 2014 Aug; 39(8):736-7. PubMed ID: 24566399
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study.
    Pommier P; Dussart S; Girinsky T; Chabaud S; Lagrange JL; Nguyen TD; Beckendorff V; D'Hombres A; Artignan X; Bondiau PY; Carrie C; Giammarile F
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):823-8. PubMed ID: 20452732
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Role of FDG PET-CT in the treatment management of Hodgkin lymphoma.
    Berriolo-Riedinger A; Becker S; Casasnovas O; Vander Borght T; Édeline V
    Cancer Radiother; 2018 Sep; 22(5):393-400. PubMed ID: 30033076
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
    Hanaoka K; Hosono M; Usami K; Tatsumi Y; Yamazoe Y; Komeya Y; Tsuchiya N; Ishii K; Sumita M
    Nucl Med Commun; 2011 Aug; 32(8):678-83. PubMed ID: 21499162
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Functional imaging of Hodgkin's disease with FDG-PET and gallium-67.
    Willkomm P; Palmedo H; Grünwald F; Ruhlmann J; Biersack HJ
    Nuklearmedizin; 1998; 37(7):251-3. PubMed ID: 9830616
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Introduction to clinical positron emission tomography.
    Agress H
    N J Med; 2000 Oct; 97(10):25-30. PubMed ID: 11064564
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhomogeneous bone marrow uptake caused by G-CSF mimics multiple bone metastases on FDG-PET.
    Nakamoto Y; Suga T; Hara T; Ishizu K; Togashi K
    Clin Nucl Med; 2010 Feb; 35(2):74-6. PubMed ID: 20090448
    [TBL] [Abstract][Full Text] [Related]  

  • 72. (18)F-FDG-PET/CT findings of granulocyte colony stimulating factor (G-CSF)-producing lung tumors.
    Morooka M; Kubota K; Murata Y; Shibuya H; Ito K; Mochizuki M; Akashi T; Chiba T; Nomura T; Ito H; Morita T
    Ann Nucl Med; 2008 Aug; 22(7):635-9. PubMed ID: 18756367
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prospective Evaluation of 18F-Fluorodeoxyglucose Uptake in Postischemic Myocardium by Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging as a Prognostic Marker of Functional Outcome.
    Rischpler C; Dirschinger RJ; Nekolla SG; Kossmann H; Nicolosi S; Hanus F; van Marwick S; Kunze KP; Meinicke A; Götze K; Kastrati A; Langwieser N; Ibrahim T; Nahrendorf M; Schwaiger M; Laugwitz KL
    Circ Cardiovasc Imaging; 2016 Apr; 9(4):e004316. PubMed ID: 27056601
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diffusion-weighted MRI compared to FDG PET-CT in the staging and response assessment of Hodgkin lymphoma.
    Marzolini M; Wong WL; Ardeshna K; Padhani A; D'Sa S
    Br J Haematol; 2012 Mar; 156(5):557. PubMed ID: 22150023
    [No Abstract]   [Full Text] [Related]  

  • 75. Decisional early interim (18)F-fluoro-2-deoxy-D-glucose positron emission tomography after two cycles of chemotherapy in de novo Hodgkin lymphoma.
    Iltis A; Eder V; Blasco H; Colombat P; Sénécal D
    Acta Haematol; 2015; 133(2):172-8. PubMed ID: 25301496
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The impact of FDG positron emission tomography imaging on the management of lymphomas.
    Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
    Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
    [TBL] [Abstract][Full Text] [Related]  

  • 77. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.
    Adams HJA; Kwee TC
    Semin Oncol; 2017 Dec; 44(6):404-419. PubMed ID: 29935902
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Intravenacaval invasion of classical Hodgkin lymphoma detected with
    Makita S; Kurihara H; Tobinai K
    Lancet Oncol; 2017 Apr; 18(4):e233. PubMed ID: 28368262
    [No Abstract]   [Full Text] [Related]  

  • 79. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C; Lépine M; Verreault J; Bénard F
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Is [(18)F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment?
    Brepoels L; Stroobants S
    Hematol Oncol Clin North Am; 2007 Oct; 21(5):855-69. PubMed ID: 17908624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.